M&A · Healthcare · Buyer's industry: Biological Products, (No Diagnostic Substances)
Talaris Therapeutics, Inc. to acquire Tourmaline Bio
Announced Jun 22, 2023 · Closed Oct 20, 2023 · Private target
Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll stock$3.43 per share
Transaction
- Acquirer
- Talaris Therapeutics, Inc. (TALS)
- Target
- Tourmaline Bio
- Buyer type
- Strategic
- Offer price per share
- $3.43
- Enterprise value
- —
- Status
- Closed Oct 20, 2023
Deal protections
Not disclosed for private-company acquisitions.
Advisors
- To the acquirer
- Leerink Partners
- To the target
- Not disclosed
Classification
- Sector
- Healthcare
- Buyer's industry
- Biological Products, (No Diagnostic Substances)